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Purpose: To evaluate the possibility of genetic involvement in retinopathy of prematurity (ROP). Although ROP is most
often associated with low birthweight and low gestational age, these factors do not necessarily predict the severity of ROP.
The  possible  involvement  of  other  factors,  including  genetic  variants,  has  been  considered.  Familial  exudative
vitreoretinopathy (FEVR) is a hereditary vitreoretinal disorder with clinical manifestations similar to those of ROP. Three
genes  involving  the  wingless/int1  (Wnt)  receptor  signaling  pathway—FZD4  for  frizzled  4,  LRP5  for  low-density
lipoprotein receptor-related protein 5, and ND for Norrie disease protein—are associated with the development of FEVR.
Methods: In the present study, 17 Japanese patients with advanced ROP were screened for these three candidate genes
of FEVR. Genomic DNA from each patient was subjected to PCR and direct sequencing of the ND, FZD4, and LRP5
genes.
Results: One patient had a heterozygous mutation in the 5′ untranslated region of the ND gene. Another had a leucine
insertion in the signal peptide of LRP5. None showed any mutation in FZD4.
Conclusions: These findings suggest that genetic changes in the Wnt receptor signaling pathway associate to the
development of advanced ROP.
Retinopathy of prematurity (ROP) is a vasoproliferative
disorder of the eye affecting premature neonates and is a
leading cause of visual loss in children even in developed
countries. However, the pathogenesis of advanced ROP is not
fully understood. It is known to occur in association with
environmental factors, such as preterm gestational age and
early  oxygen  exposure,  but  the  same  factors  can  lead  to
differing ROP phenotypes [1]. ROP regresses spontaneously
in some patients but progresses rapidly to a severe stage in
others. In addition, the incidence of advanced ROP varies
among different ethnic groups [2]. These facts suggest that
various internal factors, especially genetic variants, may be
involved in the development of ROP [3].
Familial  exudative  vitreoretinopathy  (FEVR)  is  a
hereditary vitreoretinal disorder with clinical manifestations
similar  to  those  of  ROP.  FEVR  is  known  to  have  three
inheritance  patterns:  autosomal  dominant  (AD)  [4];
autosomal recessive (AR) [5]; and X-linked recessive (XL)
[6]. Four genes have been identified as candidates for FEVR:
mutations of the Norrie disease (ND) gene have been found
in XL-FEVR (the ND gene encodes the Norrie disease protein
[NDP], Norrin) [7-9]; mutations of the FZD4 gene encoding
frizzled 4 have been observed in AD-FEVR [10,11]; and the
LRP5 gene encoding low-density lipoprotein receptor-related
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protein 5 (LRP5) is reported to show mutations in both AD-
FEVR [11] and AR-FEVR [12]. Each molecule encoded by
the above three genes participates in the wingless/integrated
(Wnt) receptor signaling pathway. Norrin acts as a ligand in
the Wnt receptor-β-catenin signaling transduction pathway by
binding to frizzled 4 [13]. In the eye, Norrin plays roles in the
recognition  signal  for  targeting  neuronal  and  retinal
connections and in angiogenesis during retina development
[14].  Frizzled  4  belongs  to  the  frizzled  family  of  Wnt
receptors,  and  an  FZD4  knockout  mouse  model  has
demonstrated the importance of this pathway in angiogenesis
and retinal development [10]. LRP5 is a member of the low-
density  lipoprotein  receptor  family.  In  Wnt  signaling
pathways, LRP5 forms a complex with frizzled 4, which acts
as a functional receptor pair to activate the canonical Wnt-β-
catenin pathway [15]. LRP5-deficient mice show a delay in
hyaloid vessel regression, suggesting that LRP5 dysfunction
can  cause  abnormal  vascularization  during  retinal
development [16]. Recently, another gene, TSPAN12, which
is involved in the Norrin-β-catenin signaling pathway, has
been found to be responsible for AD-FEVR [17-19]. Because
of the resemblance between ROP and FEVR, genetic changes
in  the  Wnt  receptor  signaling  pathway  during  retinal
development  are  considered  to  be  likely  risk  factors  for
advanced  ROP.  This  idea  is  supported  by  several  recent
studies involving screening for ND and FZD4 gene mutations
in ROP [20-25].
In the present study, we investigated whether the three
genes responsible for FEVR are associated with advanced
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2572ROP and whether any association is related to ethnicity. This
report discusses our findings regarding the Wnt signaling
pathway and its effects on retinal development.
METHODS
Patients: Seventeen premature infants (12 boys and 5 girls)
were enrolled in this study via a protocol approved by the
internal review boards of the National Center for Child Health
and Development (Tokyo, Japan) and of the Nippon Medical
School (Tokyo, Japan); informed consent was obtained from
the  parents  of  all  of  the  subjects.  Each  patient  was  of  a
gestational age of less than 32 weeks, had a birthweight of less
than 1,500 g, had undergone eye surgery, and had retinal
findings consistent with advanced ROP (Table 1). The stage
of  ROP  was  determined  by  trained  ophthalmologists
according to the international classification of retinopathy of
prematurity [26].
Genetic analysis: Genomic DNA was isolated from peripheral
blood and amplified with PCR. Each pair of oligonucleotide
primers is provided in Table 2 and Table 3. To design the
primers and identify the gene variations, we used reference
complementary  cDNA  sequences  of  ND  (NM  000266.3),
FZD4 (NM 012193.1), and LRP5 (NM 002335.1) obtained
from  GenBank  (National  Center  for  Biotechnology
Information). The ND gene had three exons, and three pairs
of primers were used to amplify each exon. The primer pairs
for exons 1 and 2 covered the 5′ untranslated region (UTR)
and coding region, and the primer pair for exon 3 amplified
the coding region. An FZD4 gene with two coding regions
was  amplified  with  seven  primers  (Table  2).  Primers  1A
forward and 1B reverse were used to detect exon 1, including
the 5′ UTR and coding region. The internal primer BF was
used to detect the coding region. Exon 2 had a long coding
region so it was amplified in two overlapping segments, A and
B. LRP5 consisted of 23 exons and encoded 1,615 amino
acids. Each exon was amplified with the primer pairs listed in
Table 3. The primer pair for exon 1 amplified the coding
region and part of the 5′ UTR. Two pairs were used to detect
exon 23 including the 3′ UTR.
PCR was performed with LA Taq polymerase (Takara
Bio,  Otsu,  Japan)  according  to  the  manufacturer’s
recommended protocol. For ND and the A set of FZD4, 10X
LA PCR™ buffer II (Takara Bio) was used. GC buffer I
(Takara  Bio)  was  used  for  the  other  primer  pairs.  The
amplification conditions for ND and FZD4 involved 30 cycles
of denaturation at 98 °C for 30 s, annealing at 58 °C for 30 s,
and extension at 72 °C for 1 min. For LRP5, amplification was
performed using 30 cycles of denaturation for 30 s at 98 °C,
followed by 30 s at 61 °C. The PCR products were purified
with a PCR clean-up kit (Macherey-Nagel, Düren, Germany)
and  sequenced  with  BigDyeTM  Terminator  version  3.1
(Applied Biosystems, Foster city, CA) on an ABI PRISM®
310 Genetic Analyzer (Applied Biosystems).
RESULTS
Of  the  17  infants,  12  were  boys  and  five  were  girls.
Birthweights  ranged  from  458  to  1,212  g  with  a  mean
(±standard deviation [SD]) of 732±221 g; gestational ages
ranged from 23 to 29 weeks with a mean (±SD) of 24.3±1.9
weeks. Of the cases of ROP in the patients' 34 eyes, four were
classified as ROP stage 3, 13 as stage 4A, one as stage 4B,
and 16 as stage 5. Fifteen of the patients showed aggressive
posterior  (AP)  ROP,  and  the  others  had  classical  ROP.
Fourteen had undergone surgery on both eyes, and the other
TABLE 1. LIST OF PATIENTS ENROLLED IN THIS STUDY.
Case
number Sex
Gestational
age (week)
Birthweight
(g)
Stage of ROP
right/left Type of ROP
Surgery
received Operation
1 M 27 1,084 4A/4A classic ROP both eyes buckling
2 M 25 972 5/5 AP-ROP both eyes vitrectomy
3 F 26 906 4A/4A AP-ROP both eyes vitrectomy
4 M 23 596 4A/4A AP-ROP both eyes vitrectomy
5 F 29 1212 4A/3 AP-ROP right eye vitrectomy
6 M 23 512 5/5 AP-ROP both eyes vitrectomy
7 F 23 642 5/5 AP-ROP both eyes vitrectomy
8 M 24 670 4A/5 AP-ROP both eyes vitrectomy
9 M 23 542 5/5 AP-ROP both eyes vitrectomy
10 F 24 588 4A/3 AP-ROP both eyes vitrectomy
11 M 23 747 4A/3 AP-ROP right eye vitrectomy
12 M 27 998 4A/4A AP-ROP both eyes vitrectomy
13 M 23 458 5/5 AP-ROP both eyes vitrectomy
14 M 23 560 4B/4A AP-ROP both eyes vitrectomy
15 M 23 676 5/3 classic ROP right eye vitrectomy
16 F 23 708 5/5 AP-ROP both eyes vitrectomy
17 M 24 576 5/5 AP-ROP both eyes vitrectomy
          Stage of ROP was classified based on ICRP. AP-ROP; aggressive posterior ROP.
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and buckling on one eye (Table 1).
Sequencing of three genes was performed. On ND gene
screening, one patient (#10) showed a heterozygous A>G
mutation  in  the  5′  UTR  of  exon  1  at  position  237.  This
mutation was not found in 51 unaffected Japanese subjects. In
one patient (#15) LRP5 gene analysis revealed a heterozygous
3-bp insertion within the CTG repeat region of exon 1, which
introduced another leucine insertion in the polyleucine region
within  the  signal  peptide  (Figure  1).  This  insertion  was
confirmed with antisense sequence (data not shown). This
insertion was not found in 28 unaffected Japanese subjects.
No FZD4 mutations were found in any of the patients.
DISCUSSION
A genetic involvement in advanced ROP has been suspected
for  a  decade.  In  the  present  study  we  performed  genetic
screening of three molecules involved in the Wnt signaling
pathway  in  17  Japanese  infants  with  advanced  ROP
(screening  patients  with  uniform  ethnic  backgrounds  is
advantageous because genetic polymorphisms due to racial
TABLE 2. PRIMER SEQUENCE FOR ND AND FZD4 GENE AMPLIFICATION.
Name Primer sequence (5′> 3′) Product size (bp)
NDP-1 F: CGCCTGATTGATATATGACTGCAATGGC 322
R: GCTCGGTTTGGAAAGAAGCGATTTCCT
NDP-2 F: TTCTGGGTAAATAATTCTGGGG 471
R: GTTTCTGAGGGAAATGCTCTCCTCACA
NDP-3 F: TAAGGTTGTGGCATGCCCACAGAGTAA 690
R: CAGAAGATGTCCCAGGAAAAGCTGGGCTTT
FZD4-1A F: ATAATTTTAGCGCCGCGAGCCTCCAG 771
R: GAAATCACTTTTCCAGGAGAGCTGTCTCC
FZD4-1B F: CAAACTGGGGGTGTCTGCCAGAGCA 475
R: GAAATCACTTTTCCAGGAGAGCTGTCTCC
FZD4-2A F: GGGAGCATTTGGTCAAACTTCCAAGTC 757
R: GAGTGTCAGAATAACCCACCAAATGGAGCT
FZD4-2B F: CCTGTTCTCATCCAAGAAGGACTTAAGAA 781
R: TTCAAAATGAAGAAAGCATGGAGGCTGACT
TABLE 3. PRIMER SEQUENCE FOR LRP5 GENE AMPLIFICATION.
Name Forward sequence (5′→3′) Reverse Sequence (5′→3′) Product size (bp)
Exon 1 TCCTCCCCGTCGTCCTG ATTGTCCGAGCAACCCG 269
Exon 2 CTTAGCCAGTGGCCCTCA AGAGAGAGATGGTGACACT 496
Exon 3 TCTGTGTTAGCTGCTTCTCTT CCAGGACTGCGTGGGTA 259
Exon 4** GATGGCTCCTCCACCCCGCT GCGCCCCAGCCGGCACT 250
Exon 5** CTCATTCAGAAACAAGTGACGGTCCTC GTCCCGTCCCACCGCCT 216
Exon 6 CTGCTGCAGGCCCTTGA TCTCCCTCTCGCCTGTG 506
Exon 7 GTCATGGACTTCTGCTTCTT TGGCCTCCTGGATCAAAC 235
Exon 8 TGGCCCATCCAGACCTAT CAAGTCTGCATGGCTGAG 298
Exon 9 GCATTCATTGTGTGGCTTG AAGCCTTTGAGGCAGGA 446
Exon 10 CTTTTCCTCCTCACCTGCT GGTGAACACAAGGACGC 289
Exon 11 AGACTCACTGAGCCTGC GCCCTCCATGACCAGAAG 261
Exon 12 CCTTTGCTGACACCGTG GAAGCTCCTTTCAGCGT 440
Exon 13 CCTGCAGCCCTGTCTTT GCCTTGGGAAGCACACC 271
Exon 14 CTCAGGAGTCTTGGTTTCTTT GCATTCGGCAGAAGACAC 308
Exon 15 CCCACACCCGTCCTTCA GGGTGTCTGCGGTTAGG 263
Exon 16 GAGGTCAGCACTGCTCA GGTCGGGTTTAGAGGCCA 301
Exon 17 AGAGCCTGACCTCTGTTT TACCTGTCCATCACCCCAA 206
Exon 18 GGCTGCGTGTGATGTTC GGTCTTGGCAGAGCCTTGA 307
Exon 19 AGCCTCTCTGAGTGCAT TAAACTCCACGTTCCTGGG 208
Exon 20 GGCCACCTCTTTCTGTTT AGATCATTCCATATCTCAGGCTC 294
Exon 21** GAGTCTCGTGGGTAGTGGGA AGAAAGCAAGGCATGCCTCAGAG 245
Exon 22 CTGGCGAGGCTCTAAGT CCCAATGGCCATGGAGG 174
Exon 23A* CTCCTCTGTGTGTGTCCC TCAGGATGAGTCCGTGC 286
Exon 23B* CTACTTCCATCTCTTCCCGC CGAAAGAATGGCAGTTCTGTT 271
             Primer sequences obtained from Gong et al. [16] ** Exon 23 was amplified in two overlapping segments, A and B.
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in the 5′ UTR of the ND gene, and another had a 3-bp insertion
resulting in one amino acid insertion in the signal peptide of
the LRP5 gene. These findings suggest an association between
genetic factors and the development of ROP.
The three genes chosen for investigation in this study are
responsible for FEVR and are involved in retinal development
through the Wnt signaling pathway. The ND gene mutation
that  causes  XL-FEVR  has  been  identified.  Because  the
incidence of severe ROP is higher among males than among
females,  the  abnormality  of  the  X  chromosome,  which
includes the ND gene, might be one of factors that influences
the severity of ROP [27]. Several studies have demonstrated
ND gene variants in ROP [20-22]. In this study, one patient
showed a heterozygous single base-pair alternation in the 5′
UTR  at  position  237  with  an  A  to  G  nucleotide  change.
Because the 5′ UTR is responsible for transcription regulation
and translation efficiency, this mutation may have altered
gene regulation. An inability to activate the Wnt receptor-β-
catenin  pathway  results  in  the  early  abrogation  of
neurosensory and vascular development [14]. Several reports
have described genetic variants in the 5′ and 3′ UTRs of the
ND gene in patients with ROP, but most mutations have been
detected  within  the  coding  region  in  patients  with  Norrie
disease  [28].  ROP  and  Norrie  disease  have  different
phenotypes and time of onset as well as speed of disease
progression;  while  Norrie  disease  causes  bilateral  retinal
malformation,  mental  retardation,  and  deafness,  the  main
features of ROP are abnormal retinal vascular development.
It has been speculated that incomplete ND proteins with amino
acid changes result in malformation of the ocular tissues,
whereas inappropriate gene expression affects retinal vascular
conformation.
Several reports have referred to the role of the FZD4 gene
in ROP [23-25]. Four missense mutations have been reported
in severe ROP. Extensive screening of the 5′ UTR and coding
region in our study failed to detect any genetic variants, and
further  investigation  is  required  to  clarify  the  role  of  the
FZD4 gene in advanced ROP.
Although several mutations of LRP5 have been found in
FEVR, this study is, to our knowledge, the first to perform
genetic screening in ROP. We screened the entire coding
region  and  3′  UTR  of  LRP5.  Due  to  the  presence  of  a
pseudogene on chromosome 22 that has high homology with
the LRP5 5′ UTR, it is difficult to isolate the entire 5′ UTR
with PCR [16]. We detected a heterozygous polymorphism in
one patient—a 3-bp insertion at the CTG repeat region in exon
1,  leading  to  the  addition  of  a  leucine  amino  acid  to  the
Figure 1. Sequence chromatograms of mutations in retinopathy of prematurity. Left: The chromatogram of ND gene exon 1. It shows the
antisense sequence between nucleotide 231 and 245. Retinopathy of prematurity (ROP) #10 shows a heterozygous mutation at 237 T->C.
Right: The chromatogram of LRP5 gene exon 1. C, D indicate a sense sequence including CTG repeat regions. The text below each normal
chromatogram represents a mutated sequence. ROP #15 shows a heterozygous 3-bp insertion (CTG) that introduced another leucine insertion
in the polyleucine region. A, C indicate a sequence of an unaffected individual. B indicates a sequence of ROP #10. D indicates sequence of
ROP #15.
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2575polyleucine residue within the signal peptide. Therefore, the
genetic variant in our case with the insertion of a single leucine
in the signal peptide might lead to insufficient translocation
during protein processing and affected retinal development.
In functional assays for the LRP5 signal peptide variants, one
leucine insertion in the polyleucine residue impairs Norrin
signal transduction [29]. The same group Chung et al. [29] has
identified that approximately 10% of German and Turkish
unaffected  subjects  have  a  heterozygous  allele  with  10
leucines in the LRP5 signal peptide residue. In contrast, none
of the 28 unaffected subjects had this insertion in our study.
This may be due to ethnic background differences. PCSK9, a
gene implicated in cholesterol metabolism, is known to have
polymorphism  within  signal  peptide  polyleucine  stretches
among normal subjects. The heterozygous carriers of a 10-
leucine allele had lower low-density lipoprotein cholesterol
concentration  compared  to  homozygous  carriers  of  a  9-
leucine  allele  [30].  Taken  together,  we  speculate  that  the
genetic  change  in  our  case  may  have  influenced  retinal
development under premature circumstances.
In conclusion, through analysis of genes involving the
Wnt receptor signal pathway, we have identified two genetic
variants  in  advanced  ROP.  Our  results  suggest  that
abnormality  in  the  Wnt  signaling  pathway  during  retinal
development  may  associate  to  severe  ROP.  Although  the
mutation and polymorphism are implicated in a small number
of  cases,  the  risk  factors  for  advanced  ROP  might  be
polygenetic. Additionally, the comparison of genetic change
between severe and mild cases can help clarify the etiology of
ROP; however, a mild case sample was not available to us.
Unfortunately,  we  are  unable  to  determine  whether  these
genetic changes are de novo or inherited because the parents
declined to be tested.
Extensive  genetic  analysis  with  an  increased  sample
number and genes, including TSPAN12, should lead to a better
understanding of the pathogenesis of ROP.
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